In Re Prempro Products Liability Litigation

474 F. Supp. 2d 1040, 2007 WL 484553
CourtDistrict Court, E.D. Arkansas
DecidedFebruary 9, 2007
Docket4:03CV1507-WRW, 4:05CV00497
StatusPublished

This text of 474 F. Supp. 2d 1040 (In Re Prempro Products Liability Litigation) is published on Counsel Stack Legal Research, covering District Court, E.D. Arkansas primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
In Re Prempro Products Liability Litigation, 474 F. Supp. 2d 1040, 2007 WL 484553 (E.D. Ark. 2007).

Opinion

474 F.Supp.2d 1040 (2007)

In re PREMPRO PRODUCTS LIABILITY LITIGATION.
Helene Rush, Plaintiff
v.
Wyeth, Defendant.

Nos. 4:03CV1507-WRW, 4:05CV00497.

United States District Court, E.D. Arkansas. Western Division.

February 9, 2007.

Brian Madden, Jan P. Helder, Jr., Patrick Stueve, Todd E. Hilton, Stueve Siegel Hanson Woody LLP, Kansas City, MO, Clinton A. Krislov, Jason P. Stiehl, Krislov & Associates, Ltd., Chicago, IL, D. Aaron Rihn, Mark T. Coulter, Peirce, Raimond & Coulter, Henry H. Wallace, Wallace, Barozzini, Harvey & Zimmaro, Pittsburgh, PA, Eileen L. McGeever, Rushall & McGeever, Carlsbad, CA, James A. Morris, Jr., Moore Landrey L.L.P., Beaumont, TX, Kathleen Dailey, Michael L. Williams, Williams, Love, O'Leary, Craine & Powers, P.C., Portland, OR, Kenneth M. Suggs, Janet, Jenner & Suggs LLC, Columbia, SC, Michel F. Mills, Nashville, TN, Patricia Mitchell, Shawn F. Khorrami, Law Offices of Shawn Khorrami, Van Nuys, CA, Paul W. Odenwald, Jr., Odenwald *1041 Law Firm, Metairie, LA, Richard S. Lewis, Cohen, Milstein, Hausfeld & Toll, P.L.L.C., Washington, DC, Robert K. Jenner, Janet, Jenner & Suggs, LLC, Baltimore, MD, Russell D. Marlin, William Gary Holt, Gary Eubanks & Associates, Little Rock, AR, Tobias L. Millrood, Schiffrin, Barroway, Topaz & Kessler, LLP, Radnor, PA, W. James Singleton, Singleton Law Firm, Shreveport, LA, Zoe B. Littlepage, Littlepage Booth, Houston, TX, James Rodney Nixon, Edward A. Williamson Law Firm, Philadelphia, MS, Russell G. Thornton, Stinnett Thiebaud & Remington, L.L.P., Dallas, TX, for Prempro Products Liability Litigation.

Leslie Frank Weisbrod, Morgan & Weisbrod, William Burton Curtis, Law Offices of Miller And Curtis, L.L.P., Dallas, TX, Kathleen Flynn Peterson, Robins, Kaplan, Miller & Ciresi, Minneapolis, MN, for Plaintiff.

Christy D. Jones, Butler, Snow, O'Mara, Stevens & Cannada, Jackson, MS, F. Lane Heard, III, Lisa M. Duggan, Williams & Connolly, Washington, DC, Lyn Peeples Pruitt, Mitchell, Williams, Selig, Gates & Woodyard, P.L.L.C., Little Rock, AR, Jane E. Bockus, Clark, Thomas & Winters, San Antonio, TX, for Defendant.

ORDER

WILSON, District Judge.

Pending is Defendant's Motion to Strike Expert Testimony Re: Legal Conclusions of Drs. Gueriguian and Sackett[1] (a trenchant memorandum, I note with pleasure). Plaintiff has responded.[2]

Down through the years common law courts have struggled with "opinion" v. "fact" and "legal conclusions."[3] As a practicing lawyer I wrestled with these questions often (as an example, see Patterson v. State[4]).

The following questions (posed to two of Plaintiff's experts) and answers have drawn vigorous objections from Defendant's counsel:

Plaintiff's Counsel to Dr. Gueriguian:

Q. Dr. Gueriguian, let me define some terms for you. I want you to assume at the end of this trial Judge Wilson will define the term "negligence" as follows: Negligence means failure to do something which a reasonably careful drug manufacturer would do or the doing of something which a reasonably careful drug manufacturer would not do under circumstances similar to those shown by the evidence in this case. Have you understood that definition as I have read it?
A. I understand that.
Q. Dr. Gueriguian, based on the thousands of documents that you reviewed in this case, the testimony that you reviewed in this case and based on your 30-plus years of training, education and experience as it relates to the drug industry, first, do you have an opinion based on that definition as I have read it? Do you have an opinion about whether Wyeth was negligent in this case?
A. I do have an opinion.
Q. And what is your opinion?
A. That it was negligent.
Q. Let me read another definition to you. Assume with me, please, at the end of this case that Judge Wilson also defines negligence to read *1042 that a drug manufacturer has a duty to use ordinary care in its drug's design in order to protect those who will use the drug from unreasonable risk of harm while the drugs are being used for their intended purpose or any purpose which should reasonably be expected by the drug manufacturer. This duty to use ordinary care in design may include a duty to test or otherwise to discover risks which should influence the design of these drugs. Have you understood that definition as I have read it to you?
A. Yes.
Q. Again, based on the thousands of pages, of documentation that you have reviewed, based on the testimony that you have seen in this case and based on your 30-plus years of experience in this industry, first, do you have an opinion as to whether Wyeth's conduct was negligent as I have just defined it?
A. I do.
Q. And what is your opinion?
A. That it didn't use ordinary care as applied in this definition.
Q. And, therefore, was Wyeth negligent based on that definition?
A. In my opinion, yes.[5]

Plaintiff's Counsel to Dr. Sackett:

Q. Doctor, as part of your expert work on this case, have you reviewed a lot of trials that were conducted over the years on E, estrogen, and E plus P, estrogen and progestin?
A. Yes.
Q. Have you reviewed a number of Wyeth's internal documents as part of your expert review on this case?
A. Yes.
Q. Have you formulated opinions about Wyeth's conduct — that is, Wyeth's actions or inactions — with regard to testing its drugs in this case?
A. Yes.
Q. Doctor, I am going to ask you to assume at the end of this case that the judge will give instructions and definitions to the jury, and I am going to ask you to assume that the judge will instruct the jury: When I use the word "negligence" in these instructions, I mean the failure to do something which a reasonably careful drug manufacturer would do or the doing of something which a reasonably careful drug manufacturer would not do under circumstances similar to those shown by the evidence in this case. In determining whether Wyeth was negligent, you may consider the degree of skill and care ordinarily possessed and used by drug manufacturers doing work of a nature similar to that shown by the evidence in this case. A drug manufacturer is held to the skill of an expert in his business and must keep reasonably abreast of scientific knowledge and discoveries touching its product. A drug manufacturer has a duty to use ordinary care in designing its drugs in order to protect those who will use the drugs from unreasonable risk of harm while the drugs are being used for their intended purpose or for any purpose which should reasonably be expected by the drug manufacturer. This duty to use ordinary care in design may include a duty to test or otherwise discover risks which should influence the design of the drugs. Assuming that definition to be true, *1043 whether you know it to be true or not, do you have an opinion as to whether or not under that definition Wyeth was negligent in this case?
* * *
Q. Can you answer the question, Doctor? The question was, do you have an opinion under that definition?
A. Yes.
Q.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

United States v. David Michael Kelly
679 F.2d 135 (Eighth Circuit, 1982)
Angelo Fiataruolo, Angelo Veno v. United States
8 F.3d 930 (Second Circuit, 1993)
Groce v. Fidelity General Insurance Company
448 P.2d 554 (Oregon Supreme Court, 1968)
Hines v. Denver & Rio Grande Western Railroad
829 P.2d 419 (Colorado Court of Appeals, 1991)
Patterson v. State
591 S.W.2d 356 (Supreme Court of Arkansas, 1979)
Behlke v. Conwed Corp.
474 N.W.2d 351 (Court of Appeals of Minnesota, 1991)
Metot v. Danielson
780 S.W.2d 283 (Court of Appeals of Texas, 1989)
Puente v. A.S.I. Signs
821 S.W.2d 400 (Court of Appeals of Texas, 1992)
McClellan v. French
439 S.W.2d 813 (Supreme Court of Arkansas, 1969)
Roman v. Vargas
182 A.D.2d 543 (Appellate Division of the Supreme Court of New York, 1992)
Rush v. Wyeth
474 F. Supp. 2d 1040 (E.D. Arkansas, 2007)

Cite This Page — Counsel Stack

Bluebook (online)
474 F. Supp. 2d 1040, 2007 WL 484553, Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-prempro-products-liability-litigation-ared-2007.